The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

GV Long; C Lebbe; V Atkinson; M Mandala; PD Nathan; A Arance; Erika Richtig; N Yamazaki; C Robert; D Schadendorf; HAH Tawbi; PA Ascierto; A Ribas; K Flaherty; N Pakhle; A Masood; E Gasal; R Dummer

The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

GV Long
, C Lebbe
, V Atkinson
, M Mandala
, PD Nathan
, A Arance
, Erika Richtig
, N Yamazaki
, C Robert
, D Schadendorf
, HAH Tawbi
, PA Ascierto
, A Ribas
, K Flaherty
, N Pakhle
, A Masood
, E Gasal
, R Dummer

Universitätsklinik für Dermatologie und Venerologie

Publikation: Beitrag in Fachzeitschrift › Konferenzabstract

2 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	Journal of Clinical Oncology
Publikationsstatus	Veröffentlicht - 2020
Veranstaltung	56th Annual Meeting of the American Society of Clinical Oncology - online Dauer: 29 Mai 2020 → 31 Mai 2020

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Wissenschaftszweige

302 Klinische Medizin

Andere Dateien und Links

Web of Science

The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.
Long, G. (Autor*in), Lebbe, C. (Autor*in), Atkinson, V. (Autor*in), Mandala, M. (Autor*in), Nathan, P. (Autor*in), Arance, A. (Autor*in), Richtig, E. (Autor*in), Yamazaki, N. (Autor*in), Robert, C. (Autor*in), Schadendorf, D. (Autor*in), Tawbi, H. (Autor*in), Ascierto, P. (Autor*in), Ribas, A. (Autor*in), Flaherty, K. (Autor*in), Pakhle, N. (Autor*in), Masood, A. (Autor*in), Gasal, E. (Autor*in) & Dummer, R. (Autor*in)
2020
Aktivität: Vortrag oder Poster › Poster

Dieses zitieren

Long, GV., Lebbe, C., Atkinson, V., Mandala, M., Nathan, PD., Arance, A., Richtig, E., Yamazaki, N., Robert, C., Schadendorf, D., Tawbi, HAH., Ascierto, PA., Ribas, A., Flaherty, K., Pakhle, N., Masood, A., Gasal, E., & Dummer, R. (2020). The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. Journal of Clinical Oncology.

@article{9774dfaa26cc4d6e9cfe1e60c8b25108,

title = "The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.",

author = "GV Long and C Lebbe and V Atkinson and M Mandala and PD Nathan and A Arance and Erika Richtig and N Yamazaki and C Robert and D Schadendorf and HAH Tawbi and PA Ascierto and A Ribas and K Flaherty and N Pakhle and A Masood and E Gasal and R Dummer",

year = "2020",

language = "English",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

note = "56th Annual Meeting of the American Society of Clinical Oncology, ASCO 56 ; Conference date: 29-05-2020 Through 31-05-2020",

}

Long, GV, Lebbe, C, Atkinson, V, Mandala, M, Nathan, PD, Arance, A, Richtig, E, Yamazaki, N, Robert, C, Schadendorf, D, Tawbi, HAH, Ascierto, PA, Ribas, A, Flaherty, K, Pakhle, N, Masood, A, Gasal, E & Dummer, R 2020, 'The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.', Journal of Clinical Oncology.

TY - JOUR

T1 - The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

AU - Long, GV

AU - Lebbe, C

AU - Atkinson, V

AU - Mandala, M

AU - Nathan, PD

AU - Arance, A

AU - Richtig, Erika

AU - Yamazaki, N

AU - Robert, C

AU - Schadendorf, D

AU - Tawbi, HAH

AU - Ascierto, PA

AU - Ribas, A

AU - Flaherty, K

AU - Pakhle, N

AU - Masood, A

AU - Gasal, E

AU - Dummer, R

PY - 2020

Y1 - 2020

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000560368300133

M3 - Conference abstract

SN - 0732-183X

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

T2 - 56th Annual Meeting of the American Society of Clinical Oncology

Y2 - 29 May 2020 through 31 May 2020

ER -

The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

UN SDGs

Wissenschaftszweige

Andere Dateien und Links

Aktivitäten

The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

Dieses zitieren